Idiopathic hypersomnia is a rare sleep disease that causes a person to be excessively sleepy during the day even after a good or prolonged night's sleep. It also causes difficulty in waking up among patients after a night sleep or a nap. Moreover, narcolepsy and idiopathic hypersomnia are both types of hypersomnia but there are differences, which can be observed by diagnostic tests such as Polysomnography (PSG) that lies in the number of sleep-onset REM periods (SOREMPs). Patients with narcolepsy have two or more SOREMPs from Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, whereas patients with idiopathic hypersomnia do not. There are symptomatic treatment such as increase wakefullness options available for idiopathic hypersomnia, while there is not a single approved drugs for this disease.
Market Dynamics
Rising number of pipeline products and increasing cases of lifestyle diseases are some of the major factors responsible for growth of the global idiopathic hypersomnia treatment Market. For instance, in October 2020, Jazz Pharmaceuticals announced positive topline results from a phase 3 study evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic hypersomnia that showed that the trial met the primary point (measured Epworth Sleepiness Scale (ESS) and key secondary end points [Patient Global Impression of Change (PGIc) and Idiopathic Hypersomnia Severity Scale (IHSS)].
Key features of the study:
- This report provides in-depth analysis of the global idiopathic hypersomnia treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global idiopathic hypersomnia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global idiopathic hypersomnia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global idiopathic hypersomnia treatment Market
Detailed Segmentation:
- Global Idiopathic Hypersomnia Treatment Market, By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Idiopathic Hypersomnia Treatment Market, By Region:
- North America
- By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals, Inc.
- BIOPROJET
- Avadel Pharmaceuticals, Plc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Theranexus
- Fisher & Paykel Healthcare Limited
- Drive DeVilbiss Healthcare LLC
- Merck & Co. Inc.
“*” marked represents similar segmentation in other categories in the respective section.
